Recombinant Rat B7-H4 Fc Chimera Protein, CF Summary
Product Specifications
Rat B7-H4 (Phe29-Gly257) Accession # Q501W4 | IEGRMDP | Mouse IgG2a (Glu98-Lys330) |
N-terminus | C-terminus | |
Analysis
Customers also Viewed
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10085-B7
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
Reconstitution | Reconstitute at 500 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
Recombinant Rat B7-H4 Fc Chimera (Catalog # 10085-B7) inhibits anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED50 for this effect is 1-6 μg/mL.
2 μg/lane of Recombinant Rat B7‑H4 Fc Chimera (Catalog # 10085-B7) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 74-85 kDa and 150-170 kDa, respectively.
Background: B7-H4
B7-H4, also known as B7x, B7S1, and V-set domain-containing T-cell activation inhibitor 1, is a 50-80 kDa glycosylated member of the B7 family of immunomodulatory proteins (1-5). Mature rat B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with two Ig-like domains. Within the ECD, rat B7-H4 shares 90% and 99% aa sequence identity with human and mouse B7-H4, respectively. Alternate splicing of human B7-H4 generates an additional isoform that lacks the first Ig-like domain. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells (4-8). Its binding to activated T cells dampens T cell responses and induces cell cycle arrest in the T cell (3-5). Reverse signaling can induce either cell cycle arrest or apoptosis in the B7-H4 expressing cell (9, 10). B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13-15). Soluble B7-H4 functions as a decoy molecule that blocks the inhibitory influence of B7-H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).
- Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
- Salceda, S. et al. (2005) Exp. Cell Res. 306:128.
- Zang, X. et al. (2003) Proc. Natl. Acad. Sci. 100:10388.
- Prasad, V.R. et al. (2003) Immunity 18:863.
- Sica, G.L. et al. (2003) Immunity 18:849.
- Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
- Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
- Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
- Song, H. et al. (2008) Cancer Lett. 266:227.
- Park, G.B. et al. (2009) Immunology 128:360.
- Zang, X. et al. (2007) Proc. Natl. Acad. Sci. 104:19458.
- Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. 103:10391.
- Simon, I. et al. (2006) Cancer Res. 66:1570.
- Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
- Azuma, T. et al. (2009) PloS Med. 6:e1000166.
- Suh, W.-K., et al. (2006) Mol. Cell. Biol. 26:6403.
Citation for Recombinant Rat B7-H4 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
Authors: Toader, D;Fessler, SP;Collins, SD;Conlon, PR;Bollu, R;Catcott, KC;Chin, CN;Dirksen, A;Du, B;Duvall, JR;Higgins, S;Kozytska, MV;Bellovoda, K;Faircloth, C;Lee, D;Li, F;Qin, L;Routhier, C;Shaw, P;Stevenson, CA;Wang, J;Wongthida, P;Ter-Ovanesyan, E;Ditty, E;Bradley, SP;Xu, L;Yin, M;Yurkovetskiy, AV;Mosher, R;Damelin, M;Lowinger, TB;
Molecular cancer therapeutics
Species: Rat
Sample Types: Complex Sample Type
Applications: ELISA Capture
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Rat B7-H4 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Rat B7-H4 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Rat B7-H4 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image